Opaleye Management Inc.'s Form 4 filing
Tracon Pharmaceuticals, Inc. (TCON) · filed Jun 27, 2022
- Accession no.
- 0001493152-22-017826
- Filed
- Jun 27, 2022
- Trade date
- Jun 24, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $15.9K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +11,419 | $1.39F2 | +$15,872.41 | 348,733 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was purchased by the reporting person in open market transactions on the transaction date, with an average purchase price of $1.3919, and a range of $1.34-$1.40. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
Referenced by the price of 1 transaction in Table I.